The role of CXC cytokines as biomarkers and potential targets in hepatocellular carcinoma

Yonghui Wang; Jianhui Huang; Zhifeng Tian; Yuefen Zhou; Jie Yang; Yonghui Wang; Jianhui Huang; Zhifeng Tian; Yuefen Zhou; Jie Yang

doi:10.3934/mbe.2020070

Mathematical Biosciences and Engineering

2020, Volume 17, Issue 2: 1381-1395. doi: 10.3934/mbe.2020070

Previous Article Next Article

Research article Special Issues

The role of CXC cytokines as biomarkers and potential targets in hepatocellular carcinoma

1.
Department of Medical Oncology, Lishui Municipal Central Hospital, Lishui 323000, China
2.
Department of Radiotherapy, Lishui Municipal Central Hospital, Lishui 323000, China
3.
Department of Infectious Disease, Lishui Municipal Central Hospital, Lishui 323000, China

Received: 17 April 2019 Accepted: 23 October 2019 Published: 22 November 2019

Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. At present, few effective biomarkers and targets are available for prognosis and treatment of HCC. Chemokines are a group of small proinflammatory chemoattractant cytokines binding to specific G-protein-coupled seven-span transmembrane receptors, which could recruit various immune cells to diverse tissues. Mountainous evidence from cell lines, animal models, even human liver tissues indicates that CXC cytokines display a strong correlation with HCC tumorigenesis. Nevertheless, the accurate expression patterns as well as functions of these CXCLs remain unclear. This study aims to explore the mRNA transcriptional and survival analysis of CXCLs in patients with HCC from the databases involving ONCOMINE, GEPIA, and cBioPortal databases. The result showed that the mRNA expression levels of CXCL2/12/14 were significantly lower in HCC tissues than those in adjacent tissues. By contrast, the mRNA expression levels of CXCL9/10 were significantly higher in HCC tissues. The expression levels of CXCL3/5 were correlated with different tumor stages. The survival analysis demonstrated that high transcriptional levels of CLCL1/3/5/8 may exhibit poorer overall survival in patients with HCC while high CXCL2 in patients with HCC may confer better overall survival. In conclusion, our study uncovered that CXCL2/5/9/10/12/14 may be novel biomarkers for the prognosis of HCC and that CXCL1/2/3/5/8 could server as potential targets in the precise treatment of HCC.
- CXCL,
- hepatocellular carcinoma,
- biomarkers,
- prognosis
Citation: Yonghui Wang, Jianhui Huang, Zhifeng Tian, Yuefen Zhou, Jie Yang. The role of CXC cytokines as biomarkers and potential targets in hepatocellular carcinoma[J]. Mathematical Biosciences and Engineering, 2020, 17(2): 1381-1395. doi: 10.3934/mbe.2020070

Related Papers:

Abstract

Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. At present, few effective biomarkers and targets are available for prognosis and treatment of HCC. Chemokines are a group of small proinflammatory chemoattractant cytokines binding to specific G-protein-coupled seven-span transmembrane receptors, which could recruit various immune cells to diverse tissues. Mountainous evidence from cell lines, animal models, even human liver tissues indicates that CXC cytokines display a strong correlation with HCC tumorigenesis. Nevertheless, the accurate expression patterns as well as functions of these CXCLs remain unclear. This study aims to explore the mRNA transcriptional and survival analysis of CXCLs in patients with HCC from the databases involving ONCOMINE, GEPIA, and cBioPortal databases. The result showed that the mRNA expression levels of CXCL2/12/14 were significantly lower in HCC tissues than those in adjacent tissues. By contrast, the mRNA expression levels of CXCL9/10 were significantly higher in HCC tissues. The expression levels of CXCL3/5 were correlated with different tumor stages. The survival analysis demonstrated that high transcriptional levels of CLCL1/3/5/8 may exhibit poorer overall survival in patients with HCC while high CXCL2 in patients with HCC may confer better overall survival. In conclusion, our study uncovered that CXCL2/5/9/10/12/14 may be novel biomarkers for the prognosis of HCC and that CXCL1/2/3/5/8 could server as potential targets in the precise treatment of HCC.

References

[1]	J. Huaman, C. Bach, A. Iboudo, et al., Epithelial to mesenchymal transition in hepatocellular carcinoma, Precision Molecular Pathology of Liver Cancer, Springer, Cham, 2018, 131-152.
[2]	D. Y. Xie, Z. G. Ren, J. Zhou, et al., Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma, Hepatobiliary Surg. Nutr., 6 (2017), 387-396.
[3]	N. Nagarsheth, M. S. Wicha and W. Zou, Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy, Nat. Rev. Immunol., 17 (2017), 559-572.
[4]	I. Kufareva, Chemokines and their receptors: Insights from molecular modeling and crystallography, Curr. Opin. Pharmacol., 30 (2016), 27-37.
[5]	M. J. Stone, J. A. Hayward, C. Huang, et al., Mechanisms of regulation of the chemokine-receptor network, Int. J. Mol. Sci., 18 (2017), 342.
[6]	J. Vandercappellen, J. V. Damme and S. Struyf, The role of CXC chemokines and their receptors in cancer, Cancer Lett., 267 (2008), 226-244.
[7]	S. L. Zhou, Z. Dai, Z. Zhou, et al., Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma, Hepatology, 56 (2012), 2242-2254.
[8]	H. Tian, P. Huang, Z. Zhao, et al., HIF-1α plays a role in the chemotactic migration of hepatocarcinoma cells through the modulation of CXCL6 expression, Cell Physiol. Biochem., 34 (2014), 1536-1546.
[9]	S. C. Sealfon and T. T. Chu, RNA and DNA Microarrays, in Biological Microarrays, Methods in Molecular Biology, Humana Press, Totowa, 2011, 3-43.
[10]	N. Li, L. Li and Y. Chen, The Identification of Core Gene Expression Signature in Hepatocellular Carcinoma, Oxid. Med. Cell. Longevity, 2018 (2018), 1-15.
[11]	D. R. Rhodes, J. Yu, K. Shanker, et al., ONCOMINE: A cancer microarray database and integrated data-mining platform, Neoplasia, 6 (2004), 1-6. doi: 10.1016/S1476-5586(04)80047-2
[12]	Z. Tang, C. Li, B. Kang, et al., GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses, Nucleic Acids Res., 45 (2017), W98-W102.
[13]	The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumors, Nature, 490 (2012), 61-70.
[14]	N. Liu, L. Zhang, Z. Wang, et al., MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9, Oncotarget, 8 (2017), 19244-19254.
[15]	G. Dennis, B. T. Sherman, D. A. Hosack, et al., DAVID: Database for annotation, visualization, and integrated discovery, Genome Biol., 4 (2003), R60.
[16]	V. R. Mas, D. G. Maluf, K. J. Archer, et al., Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma, Mol. Med., 15 (2009), 85-94.
[17]	E. Wurmbach, Y. Chen, G. Khitrov, et al., Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma, Hepatology, 45 (2007), 938-947.
[18]	M. D. Vesely, M. H. Kershaw, R. D. Schreiber, et al., Natural innate and adaptive immunity to cancer, Annu. Rev. Immunol., 29 (2011), 235-271.
[19]	M. B. Fuertes, S. R. Woo, B. Burnett, et al., Type I interferon response and innate immune sensing of cancer, Trends Immunol., 34 (2013), 67-73.
[20]	X. Yang, X. Zhang, M. Y. Fu, et al., Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses, Cancer Cell, 25 (2014), 37-48.
[21]	X. Yu, Y. Huang, P. Collinosdoby, et al., CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts, J. Bone Miner. Res., 19 (2004), 2065-2077.
[22]	N. Salazar, D. Muñoz, G. Kallifatidis, et al., The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation, Mol. Cancer, 13 (2014), 198.
[23]	Z. Cao, B. Fu, B. Deng, et al., Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma, Cancer Cell Int., 14 (2014), 86.
[24]	T. Ding, J. Xu, F. Wang, et al., High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection, Hum. Pathol., 40 (2009), 381-389.
[25]	J. Zhou, T. Ding, W. Pan, et al., Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients, Int. J. Cancer, 125 (2009), 1640-1648.
[26]	D. M. Kuang, Q. Zhao, Y. Wu, et al., Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma, J. Hepatol., 54 (2011), 948-955.
[27]	M. N. Vansaun, A. M. Mendonsa and D. L. Gorden, Hepatocellular Proliferation Correlates with Inflammatory Cell and Cytokine Changes in a Murine Model of Nonalchoholic Fatty Liver Disease, Plos One, 8 (2013), e73054.
[28]	P. H. Killian, E. Kronski, K. M. Michalik, et al., Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2, Carcinogenesis, 33 (2012), 2507-2519.
[29]	X. Song, Z. Wang, Y. Jin, et al., Loss of miR-532-5p in vitro promotes cell proliferation and metastasis by influencing CXCL2 expression in HCC, Am. J. Transl. Res., 7 (2015), 2254-2261.
[30]	H. Xin, Y. Cao, M. Shao, et al., Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion, Int. Urol. Nephrol., 50 (2018), 861-868.
[31]	K. J. Simpson, N. C. Henderson and C. L. Bone-Larson, Chemokines in the pathogenesis of liver disease: So many players with poorly defined roles, Cli. Sci., 104 (2003), 47-63.
[32]	L. Zhang, L. Zhang, H. Li, et al., CXCL3 contributes to CD133+ CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation, Sci. Rep., 6 (2016), 27426.
[33]	S. Zhou, Z. Zhou, Z. Hu, et al., CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling, Cancer Let., 358 (2015), 124-135.
[34]	X. Li, X. Yang, E. Biskup, et al., Co-expression of CXCL8 and HIF-1α is associated with metastasis and poor prognosis in hepatocellular carcinoma, Oncotarget, 6 (2015), 22880-22889.
[35]	X. Lan, F. Xiao, Q. Ding, et al., The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2, J. Mol. Histol., 45 (2014), 689-696.
[36]	A. Zipin-Roitman, T. Meshel, O. Sagi-Assif, et al., CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells, Cancer Res., 67 (2007), 3396-3405.
[37]	T. Ren, L. Zhu and M. Cheng, CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma, Am. J. Transl. Res., 9 (2017), 2824-2837.
[38]	G. V. Shurin, R. Ferris, I. L. Tourkova, et al., Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo, J. Immunol., 174 (2005), 5490-5498.

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)